number of serious diseases, including cardiovascular disease, type II diabetes, cancer, hypertension, Alzheimer’s Disease, asthma, and wound healing. In addition, sulfur deficiencies in the diet may be directly contributing to these diseases. Patient studies in Mexico demonstrated safety and generated encouraging results in several disease conditions including infertility, cancer, and hypercholesterolemia. Sulfagenix’s lead product, SG1002, is being developed in Phase I clinical trial (http://www.clinicaltrials.gov/ct2/show/NCT01989208) in Australia by Sulfagenix Australia to treat problems associated with heart failure.